Professor
Johns Hopkins University
Baltimore, Maryland, United States
Lisa Christopher-Stine, MD is a Professor of Medicine with a joint appointment in the Department of Neurology and the Co-Founder and Director of the Johns Hopkins Myositis Center.
She is a rheumatologist specializing in inflammatory muscle diseases. She has dedicated her career to understanding and treating autoimmune muscle disorders and is the co-discoverer of the anti-HMGCR autoantibody which expanded the understanding of stain myopathy as an autoimmune disease in addition to the more known self-limited form.
Throughout her career, she has published over 150 research papers in reputed journals, which have contributed significantly to the understanding of inflammatory myopathies.
She was the 2022 Medical Champion Honoree for the Baltimore Chapter of the Arthritis Foundation and was an invited Duke University Joseph C. Greenfield Lecturer in recognition of mentoring the next generation of academic physicians.
As a clinician- scientist, she is the Principal Investigator of the Johns Hopkins Myositis Research Registry, developed by her and her colleagues, currently numbering well over 3000 patients recruited worldwide. She has a strong interest in myositis clinical phenotyping, druggable targets in myositis, the gut and skin microbiome, and patient reported outcomes in myositis.
Her dedication to patient care, paired with her robust academic contributions, has established her as a key figure in the world of autoimmune muscle diseases.
MTP03A: Meet the Professor: Myositis
Saturday, November 16, 2024
7:30 AM – 8:30 AM Eastern Time
Disclosure(s): NKarta: Consultant (Ongoing); NuVig: Advisor or Review Panel Member (Ongoing); Octapharma: Advisor or Review Panel Member (Ongoing)
MTP03B: Meet the Professor: Myositis
Saturday, November 16, 2024
11:30 AM – 12:30 PM Eastern Time
Disclosure(s): NKarta: Consultant (Ongoing); NuVig: Advisor or Review Panel Member (Ongoing); Octapharma: Advisor or Review Panel Member (Ongoing)
MCTD Is a Unique Rheumatic Disease
Sunday, November 17, 2024
3:30 PM – 3:45 PM Eastern Time
No financial relationships with ineligible companies to disclose
Sunday, November 17, 2024
4:20 PM – 4:30 PM Eastern Time
No financial relationships with ineligible companies to disclose
222: Beyond the Basics: What Makes Immunoglobulin Therapy Effective in Dermatomyositis?
Monday, November 18, 2024
12:30 PM – 1:15 PM Eastern Time
No financial relationships with ineligible companies to disclose